Overview
Jorey Chernett, identified as a ten percent holder of Neuronetics, Inc. (NASDAQ: STIM), completed purchases of common stock totaling $309,000 through two sets of transactions on April 20 and April 21, 2026. The combined acquisition was for 200,000 shares of the medical device company, executed over the two dates.
Transaction specifics
- On April 20, Mr. Chernett acquired 100,000 shares at a weighted average price of $1.58 per share. Those trades occurred at prices ranging from $1.56 to $1.59.
- On April 21, he purchased an additional 100,000 shares at a weighted average price of $1.51 per share, with trade prices between $1.50 and $1.52.
- Across both days, the purchases fell within a price band of $1.51 to $1.58 per share.
Post-transaction holdings and market context
Following these acquisitions, Mr. Chernett now directly holds 9,978,988 shares of Neuronetics common stock. Market commentary referenced in the same reporting noted the stock had returned nearly 8% over the prior week, though it remained down 49% over the previous six months. An InvestingPro assessment cited in the report indicates the stock is trading slightly above its Fair Value, with more detailed analysis available in the company’s Pro Research Report.
Recent financials and analyst reaction
Neuronetics’ fourth-quarter 2025 financial results included a mixed set of indicators. The company posted earnings per share of -$0.10, missing the consensus forecast of -$0.09 and representing an 11.11% negative surprise on EPS. Conversely, revenue came in at $41.8 million, ahead of the expected $40.66 million and constituting a 2.73% positive surprise versus estimates.
Canaccord retained a Buy rating on Neuronetics but lowered its price target from $7.00 to $3.00, citing a change in valuation assumptions despite the company reporting an operationally cash flow positive second quarter.
Corporate developments and shareholder activism
Separately, Neuronetics announced that Chief Financial Officer Steven E. Pfanstiel will depart in May 2026; the company indicated there were no disputes cited as the reason for his departure. Mr. Chernett, described as the largest independent shareholder, has urged the company’s board to evaluate strategic alternatives, including the potential sale of its transcranial magnetic stimulation business. The company responded to Mr. Chernett’s letter by reaffirming its commitment to actions intended to maximize shareholder value.
What this means
The transaction increases the direct stake of a major shareholder amid an environment of volatile share performance, recent operational updates and ongoing dialogue between a significant investor and the company’s board. The purchase and the shareholder engagement coincide with mixed quarterly results, an analyst price-target revision and an announced change in senior finance leadership.
Key points
- Insider buying: Jorey Chernett purchased 200,000 Neuronetics shares across April 20-21, 2026, totaling $309,000.
- Financial snapshot: Q4 2025 EPS missed estimates (-$0.10 vs -$0.09) while revenue topped expectations at $41.8 million.
- Corporate shifts: CFO to depart in May 2026, and Chernett has urged the board to consider strategic alternatives including a potential sale of the TMS business.
Risks and uncertainties
- Stock volatility - The share price recently moved higher over a one-week period but remains significantly lower over six months, indicating continued price risk for investors in the healthcare and medtech sectors.
- Leadership transition - The announced departure of the CFO in May 2026 introduces near-term execution risk related to financial management and reporting.
- Strategic uncertainty - Active calls from a major shareholder to pursue strategic alternatives, including a sale of the TMS business, create potential uncertainty around the company’s future structure and operations.
Note: This article presents the transaction details, financial results and corporate developments as reported.